Rather than treating a wound, Sanuwave Health's (Alpharetta, Georgia) dermaPACE technology harnesses the power of regenerative medicine to stimulate the body's own biological healing mechanism. With enrollment just completed in a pivotal phase III trial of dermaPACE to treat diabetic foot ulcers, the company is closer to launching a product that could address a $2 billion market in the U.S. and an estimated $10 billion advanced wound care market globally. (Medical Device Daily) Read More
